Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints... see more

NDAQ:APHA - Post Discussion

Aphria Inc. > Portion of CIBC updated Opinion.
View:
Post by probowler900 on Apr 12, 2021 10:20pm

Portion of CIBC updated Opinion.

EQUITY RESEARCH April 12, 2021
Earnings Update APHRIA INC.
Quorum Questions: Still Expect Deal To Close, Softness May Create Buying Opportunity Our Conclusion Today’s focus from management on voter encouragement suggests that there is at least some uncertainty on whether the proposed APHA-TLRY deal passes on its first attempt. We expect the biggest hurdle is attaining the required quorum for TLRY (50.1% of shares outstanding must vote). To be clear, we believe the deal eventually closes and creates an industry leader with potential for $100MM of synergies and a highly profitable entity with a leading share in Canada and Europe. We view today’s sell-off as overdone. This continues to be an industry that thrives on brick & mortar sales, and store restrictions have had a meaningful impact, which we expect to ebb by the summer. We reduce our price target to $23 (from $28), and APHA is rated Outperformer.
Comment by skyplt on Apr 13, 2021 6:49am
Disappointing but not entirely unexpected. At least Stifel (and ghostinthedark...credit where credit is due) had the ability and foresight to see this coming and warn before earnings. This is a harsh reminder that most analysts are only good at forecasting yesterday's weather. I have adjusted my sell order accordingly (24CDN). Once again I find myself sobered by the volatile nature of this ...more  
Comment by CommonCentsforDollars on Apr 13, 2021 10:23am
That is like giving Greasy Grego credit. Hilarious! Grabbed a few TLRY traders in this mornings pre-market @ $16.28, a beautiful bounce. 
Comment by CommonCentsforDollars on Apr 13, 2021 10:36am
Just zapped the traders $17.97. Holding my long position. Refreshed my trader powder. TLRY has a support level at $17.18 that it will likely test again later today or tomorrow. The TLRY chart is the far more important chart to look at over APHA. That is where the volume is. eom momo
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities